Kodiak Sciences (KOD) Other Non Operating Income (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Other Non Operating Income came in at -$22000.0 in Q1 2026, down 320.0% YoY from $10000.0 in Q1 2025, and up 45.0% on a QoQ basis from -$40000.0 in Q4 2025.
Analysis
Kodiak Sciences (KOD) Other Non Operating Income (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Other Non Operating Income data on file, last reported at -$22000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 320.0% year-over-year to -$22000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128000.0 (up 19.5% YoY) and the FY2025 annual result came in at -$96000.0, up 81.03% from the prior year.
- Other Non Operating Income improved to -$22000.0 in Q1 2026, from -$40000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $605000.0 in Q4 2022 to a low of -$337000.0 in Q1 2024.
- A 5-year average of -$647.06 and a median of -$38000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 1807.69% — and 2026, when it plunged 320.0%.
- Tracing KOD's Other Non Operating Income over 5 years: stood at $605000.0 in 2022, then sank by 106.45% to -$39000.0 in 2023, then sank by 43.59% to -$56000.0 in 2024, then gained by 28.57% to -$40000.0 in 2025, then jumped by 45.0% to -$22000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$22000.0 (Q1 2026), -$40000.0 (Q4 2025), and -$22000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.23 Bn | 2.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60,000.00 |
| Mar 31, 2026 | -22,000.00 |
| Dec 31, 2025 | -40,000.00 |
| Sep 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -44,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -88,000.00 |
| Mar 31, 2024 | -337,000.00 |
| Dec 31, 2023 | -39,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | -35,000.00 |
| Mar 31, 2023 | 222,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Sep 30, 2022 | -40,000.00 |
| Jun 30, 2022 | -49,000.00 |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | -114,000.00 |
| Sep 30, 2021 | -25,000.00 |